Copyright
©The Author(s) 2016.
World J Gastroenterol. Aug 21, 2016; 22(31): 7030-7045
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7030
Published online Aug 21, 2016. doi: 10.3748/wjg.v22.i31.7030
Test | Method | Uses | Comments |
IgM anti-HEV | ELISA | Acute infection | Assays vary in performance, issue of genotype applicability, poor performance in immune disorders, cross-reactive with other viral infections |
ICT (POCT) | |||
IgG anti-HEV | ELISA | Seroprevalence | Assays vary in performance |
ICT (POCT) | Acute infection | ||
Natural protection | |||
Vaccine efficacy | |||
HEV RNA | NAT | Acute infection | Viremia short-lasting, in-house assays vary in performance, advantage immune disorders |
Confirm chronicity | |||
Anti-viral response | |||
Donor screening | |||
HEV antigen | EIA | Acute infection | 81% concordance with HEV RNA |
- Citation: Khuroo MS, Khuroo MS, Khuroo NS. Hepatitis E: Discovery, global impact, control and cure. World J Gastroenterol 2016; 22(31): 7030-7045
- URL: https://www.wjgnet.com/1007-9327/full/v22/i31/7030.htm
- DOI: https://dx.doi.org/10.3748/wjg.v22.i31.7030